Balance Sheet Report Date Revenues Cost of sales Gross Profit Selling, informational & administrative expenses Research & development expenses Amortization of intangible assets Restructuring charges & certain acquisition-related costs 2020 41,908,000 8,692,000 2019 2018 51,750,000 53,647,000 10,219,000 11,248,000 33,216,000 41,531,000 42,399,000 11,615,000 14,350,000 14,455,000 9,405,000 8,650,000 8,006,000 3,436,000 4,610,000 4,893,000 600,000 747,000 1,044,000 Gain (loss) on completion of Consumer Healthcare JV transaction 6,000 8,086,000 Interest income 73,000 226,000 333,000 Interest expense 1,449,000 1,574,000 1,316,000 Royalty-related income 770,000 648,000 495,000 other expenses 63,000 2,878,000 1,628,000 Income (loss) from continuing operations before provision for taxes on income 7,497,000 17,682,000 11,885,000 Provision (benefit) for taxes on income 476,000 1,384,000 706,000 Income (loss) from continuing operations after provision for taxes on income 7,021,000 16,298,000 11,179,000 Income (loss) from discontinued operations - net of tax 2,631,000 4,000 9,000 Net income before allocation to noncontrolling interests 9,652,000 16,302,000 11,188,000 Less: net income attributable to noncontrolling interests (36,000) (29,000) (35,000) Net income attributable to Pfizer Inc. 9,616,000 16,273,000 11,153,000